JP2011521648A5 - - Google Patents

Info

Publication number

JP2011521648A5

JP2011521648A5 JP2011511825A JP2011511825A JP2011521648A5 JP 2011521648 A5 JP2011521648 A5 JP 2011521648A5 JP 2011511825 A JP2011511825 A JP 2011511825A JP 2011511825 A JP2011511825 A JP 2011511825A JP 2011521648 A5 JP2011521648 A5 JP 2011521648A5

Authority

JP

Japan

Prior art keywords

bifunctional molecule

seq

amino acid

acid sequence

bifunctional

Prior art date

2009-05-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 230000001588 bifunctional effect Effects 0.000 claims description 57
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
• 210000004027 cell Anatomy 0.000 claims description 12
• 241000725303 Human immunodeficiency virus Species 0.000 claims description 10
• 208000015181 infectious disease Diseases 0.000 claims description 9
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
• 210000004899 c-terminal region Anatomy 0.000 claims description 4
• 230000009385 viral infection Effects 0.000 claims description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 241000588724 Escherichia coli Species 0.000 claims description 2
• 241000238631 Hexapoda Species 0.000 claims description 2
• 108020004511 Recombinant DNA Proteins 0.000 claims description 2
• 230000001580 bacterial effect Effects 0.000 claims description 2
• 210000004962 mammalian cell Anatomy 0.000 claims description 2
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
• 108010048106 sifuvirtide Proteins 0.000 claims description 2
• WIOOVJJJJQAZGJ-ISHQQBGZSA-N sifuvirtide Chemical compound C([C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CO)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 WIOOVJJJJQAZGJ-ISHQQBGZSA-N 0.000 claims description 2
• 239000007787 solid Substances 0.000 claims description 2
• 210000005253 yeast cell Anatomy 0.000 claims description 2
• 241000700605 Viruses Species 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• 238000000034 method Methods 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1